Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Want to cut your energy bills? Here’s how five experts are doing it 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
TEL AVIV, Israel, March 02, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, March 27, 2017 at 8:30am Eastern Time to report fourth quarter and full-year ended December 31, 2016 financial results.
| Monday, March 27th @ 8:30am Eastern Time | |||
| Domestic: | 888-727-7622 | ||
| International: | 913-312-0384 | ||
| Conference ID: | 8563883 | ||
| Webcast: | http://edge.media-server.com/m/p/npmjtb62 | ||
| Replays, available through April 10, 2017: | |||
| Toll Free: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Conference ID: | 8563883 | ||
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979
